Sleep and depression.

James R Slaughter

PubMed · 17133757

Sleep and depression.

Abstract

Depression results in severe sleep disturbance. The "depressed brain" takes longer to initiate sleep, shortens the period to dreaming sleep, spends little or no time in "deep sleep" and is subject to hyperactive brain regions during sleep. Antidepressants rectify the sleep disturbance and restore normal sleep architecture and presumably normal brain metabolism during sleep. Early intervention may lead to a decrease in neuronal cell loss due to depression, and better long-term outcomes for mood disorders.

Explore related subjects

Depressive Disorder Humans Sleep Wake Disorders Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

James R Slaughter. Sleep and depression.. https://pubmed.ncbi.nlm.nih.gov/17133757/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Psychological morbidity and female urinary incontinence.

Female urinary incontinence is a common yet distressing condition. It affects women of all ages, but is especially common in the elderly. Its prevalence ranges from 15 to 55%, depending on age and population studied. Despite the ubiquity of female urinary incontinence, many incontinent women do not voice their suffering, and urinary incontinence has therefore been dubbed 'the silent epidemic'. The physical impact and social isolation associated with urinary incontinence lead to impairment of quality of life and psychological well-being. It is the aim of this review to discuss the epidemiology and psychological impact of urinary incontinence. The recognition and management of incontinence-related psychological morbidity are also explored.

Depressive Disorder↗

PubMed2007

Low resilience in suicide attempters: relationship to depressive symptoms.

Explore the source record for details and available documents.

Depressive Disorder↗

PubMed2007

Vagus nerve stimulation therapy in depression and epilepsy: therapeutic parameter settings.

Vagus nerve stimulation (VNS) therapy is an effective adjunctive treatment for chronic or recurrent treatment-resistant depression in adults, and for pharmacoresistant epilepsy in adults and adolescents. VNS therapy is administered through an implanted pulse generator that delivers programmed electrical pulses through an implanted lead to the left vagus nerve. Programmable pulse parameters include output current, frequency, pulse width, and ON/OFF times. Within a range of typical values, individual patients respond best to different combinations of parameter settings. The physician must identify the optimum settings for each patient while balancing the goals of maximizing efficacy, minimizing side effects, and preserving battery life. Output current is gradually increased from 0.25 mA to the maximum tolerable level (maximum, 3.5 mA); typical therapeutic settings range from 1.0 to 1.5 mA. Greater output current is associated with increased side effects, including voice alteration, cough, a feeling of throat tightening, and dyspnea. Frequency is typically programmed at 20 Hz in depression and 30 Hz in epilepsy. Pulse width is typically 250 or 500 micros. The recommended initial ON time is 30 s, followed by 5 min OFF; OFF time > ON time is recommended. As with pharmacotherapy, VNS therapy must be adjusted in a gradual, systematic fashion to individualize therapy for each patient.

Depressive Disorder↗